| Recruiting | Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicia NCT07282158 | Fred Hutchinson Cancer Center | N/A |
| Not Yet Recruiting | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence NCT07495124 | University of Washington | Phase 2 |
| Recruiting | Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions NCT07280312 | Mayo Clinic | N/A |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. NCT07267780 | National Cancer Institute, Naples | — |
| Recruiting | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer NCT06964009 | Elizabeth Stover, MD, PhD | Phase 1 |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | The Vanguard Study: Testing a New Way to Screen for Cancer NCT06995898 | National Cancer Institute (NCI) | N/A |
| Recruiting | Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatme NCT06817161 | Centre Francois Baclesse | Phase 3 |
| Recruiting | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer NCT07067255 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314 | NRG Oncology | Phase 3 |
| Completed | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovar NCT06870539 | Mayo Clinic | — |
| Recruiting | Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovar NCT06543537 | Dana-Farber Cancer Institute | N/A |
| Recruiting | OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study NCT06611072 | Gynaecologisch Oncologisch Centrum Zuid | N/A |
| Recruiting | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin NCT06677190 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Terminated | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With NCT06546553 | Pfizer | Phase 1 |
| Recruiting | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients Wit NCT06492070 | Emory University | Phase 2 |
| Recruiting | Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy NCT06475261 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinoma NCT06393543 | Radboud University Medical Center | — |
| Recruiting | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults NCT05949424 | University Medical Center Groningen | Phase 4 |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Recruiting | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Daiichi Sankyo | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors NCT06285097 | Pfizer | Phase 1 |
| Active Not Recruiting | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients NCT06028932 | Yale University | Phase 2 |
| Recruiting | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study NCT06295965 | University of Washington | — |
| Withdrawn | Intraperitoneal LSTA1 in CRS-HIPEC NCT06216561 | University of California, San Diego | Phase 1 |
| Recruiting | Access to Genetic Testing in Underserved Patients With Cancer NCT06422455 | University of Southern California | N/A |
| Withdrawn | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma NCT05714306 | Centre Hospitalier Universitaire Vaudois | Phase 1 / Phase 2 |
| Recruiting | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer NCT05927818 | Istanbul University | N/A |
| Recruiting | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer NCT05773859 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Unknown | Itraconazole in Advanced Ovarian Cancer NCT05591560 | Tanta University | N/A |
| Completed | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer NCT05494580 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Terminated | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer NCT05261490 | Pfizer | Phase 1 / Phase 2 |
| Completed | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) NCT05446870 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) NCT05429970 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Opti NCT05415527 | Institut Bergonié | N/A |
| Terminated | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors NCT05194735 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving NCT04997096 | Dana-Farber Cancer Institute | N/A |
| Unknown | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer NCT05310344 | Lei Li | Phase 2 |
| Unknown | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer NCT05311579 | Lei Li | Phase 2 |
| Terminated | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in NCT05200364 | Sutro Biopharma, Inc. | Phase 1 |
| Completed | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Usin NCT06789224 | Lindis Bloodcare GmbH | N/A |
| Completed | IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection NCT06977334 | Maharajgunj Medical Campus | — |
| Active Not Recruiting | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics NCT04905082 | City of Hope Medical Center | N/A |
| Unknown | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Cl NCT05180851 | Shanghai Fengxian District Central Hospital | EARLY_Phase 1 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid NCT05001347 | I-Mab Biopharma US Limited | Phase 2 |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours NCT04969835 | Avacta Life Sciences Ltd | Phase 1 |
| Recruiting | Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma NCT04562623 | Centre Leon Berard | — |
| Recruiting | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of Intra-operative Imaging in Women With Ovarian Cancer NCT04878094 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. NCT05610501 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors NCT04917744 | Mayo Clinic | — |
| Terminated | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors NCT04628780 | Pfizer | Phase 1 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous NCT06827353 | Centre Hospitalier Universitaire de Nīmes | — |
| Recruiting | A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovari NCT04251052 | NRG Oncology | N/A |
| Terminated | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NCT04442126 | Numab Therapeutics AG | Phase 1 / Phase 2 |
| Completed | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach NCT04902144 | Fred Hutchinson Cancer Center | N/A |
| Completed | A Trial Evaluating TG4050 in Ovarian Carcinoma. NCT03839524 | Transgene | Phase 1 |
| Active Not Recruiting | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal a NCT04147494 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives NCT04257045 | M.D. Anderson Cancer Center | — |
| Terminated | A Safety Study of SGN-CD47M in Patients With Solid Tumors NCT03957096 | Seagen Inc. | Phase 1 |
| Active Not Recruiting | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) NCT03842982 | Centre Oscar Lambret | Phase 3 |
| Active Not Recruiting | Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplat NCT04310826 | M.D. Anderson Cancer Center | N/A |
| Terminated | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy NCT03382574 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT03756818 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Canc NCT03748186 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma NCT03302884 | Institut Paoli-Calmettes | N/A |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma NCT06972693 | European Institute of Oncology | Phase 4 |
| Completed | Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer NCT03562533 | Konkuk University Medical Center | — |
| Active Not Recruiting | PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer NCT03965481 | M.D. Anderson Cancer Center | N/A |
| Completed | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivo NCT03372720 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery NCT03379376 | Wake Forest University Health Sciences | N/A |
| Completed | 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer NCT03857087 | University of California, San Francisco | — |
| Recruiting | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 NCT03296826 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | — |
| Unknown | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma NCT05576519 | Sohag University | — |
| Completed | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer NCT03180294 | NRG Oncology | Phase 2 |
| Completed | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Car NCT03085225 | Institut Bergonié | Phase 1 |
| Terminated | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer NCT03029585 | NanOlogy, LLC | Phase 2 |
| Completed | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight NCT03027479 | University Hospital, Tours | N/A |
| Withdrawn | An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in O NCT02878980 | City of Hope Medical Center | N/A |
| Withdrawn | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer NCT02530606 | Stanford University | N/A |
| Terminated | Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer NCT02708511 | Sanjiv Sam Gambhir | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265 | National Cancer Institute (NCI) | Phase 2 |
| Completed | HE4 as a Relapse Biomarker in Ovarian Cancers NCT02595281 | Institut de Cancérologie de Lorraine | N/A |
| Unknown | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or NCT02584478 | Advenchen Laboratories, LLC | Phase 3 |
| Completed | REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progress NCT02584465 | ARCAGY/ GINECO GROUP | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma NCT02487693 | The First People's Hospital of Changzhou | Phase 2 |
| Terminated | Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and The NCT02412124 | City of Hope Medical Center | N/A |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malig NCT02578888 | Albert Einstein College of Medicine | N/A |
| Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Und NCT02315469 | NRG Oncology | — |
| Completed | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma NCT02297958 | Rennes University Hospital | — |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With O NCT02166905 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Sy NCT02194387 | M.D. Anderson Cancer Center | N/A |
| Unknown | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian C NCT02244502 | NovoCure Ltd. | Phase 1 / Phase 2 |
| Terminated | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses NCT02218502 | Maastricht University Medical Center | N/A |
| Unknown | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage NCT03150121 | Sheba Medical Center | N/A |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma NCT02083536 | University of Miami | Phase 1 |
| Completed | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies NCT02025985 | Karyopharm Therapeutics Inc | Phase 2 |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Terminated | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma NCT01936974 | Western Regional Medical Center | Phase 2 |
| Active Not Recruiting | Prophylactic Salpingectomy With Delayed Oophorectomy NCT01907789 | M.D. Anderson Cancer Center | N/A |
| Completed | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma NCT01519869 | Rachel Miller | Phase 2 |
| Completed | Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovar NCT01657747 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Active Not Recruiting | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT01366144 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Perit NCT01295489 | Gynecologic Oncology Group | — |
| Terminated | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer NCT01312376 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Withdrawn | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-01 NCT01445275 | Gynecologic Oncology Group | — |
| Terminated | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy NCT01175772 | HaEmek Medical Center, Israel | Phase 2 |
| Completed | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Lin NCT01709487 | Jules Bordet Institute | Phase 1 / Phase 2 |
| Completed | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Stud NCT01091428 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer NCT00862355 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies NCT02073500 | Oslo University Hospital | — |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma NCT00853307 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian C NCT01481701 | Jules Bordet Institute | Phase 2 |
| Completed | Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors NCT00756847 | Sanofi | Phase 1 |
| Completed | Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer o NCT00679783 | AstraZeneca | Phase 2 |
| Completed | Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma NCT00721890 | CHU de Quebec-Universite Laval | Phase 2 |
| Completed | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma NCT00868192 | Washington University School of Medicine | Phase 2 |
| Completed | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer NCT00445887 | Gynecologic Oncology Group | Phase 2 |
| Withdrawn | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients a NCT00659399 | NYU Langone Health | Phase 1 |
| Completed | A Phase I Study of Intraperitoneal Hyperthermic Docetaxel NCT00474669 | University of Louisville | Phase 1 |
| Completed | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen NCT00623831 | Ludwig Institute for Cancer Research | Phase 1 |
| Recruiting | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors NCT00488878 | M.D. Anderson Cancer Center | — |
| Terminated | Doxil and Gemcitabine in Recurrent Ovarian Cancer NCT00312650 | Women and Infants Hospital of Rhode Island | Phase 2 |
| Completed | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remov NCT00305695 | Gynecologic Oncology Group | Phase 2 |
| Completed | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin NCT00181701 | Massachusetts General Hospital | Phase 2 |
| Unknown | IGFBP-3 in Ovarian Cancer Invasion NCT00154986 | National Taiwan University Hospital | N/A |
| Completed | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Rec NCT01689714 | Endocyte | Phase 2 |
| Completed | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary P NCT00183794 | University of Southern California | Phase 2 |
| Completed | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer NCT00214058 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study NCT00715286 | All India Institute of Medical Sciences | Phase 3 |
| Terminated | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer NCT00047632 | InterMune | Phase 3 |
| Active Not Recruiting | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) NCT01696994 | National Cancer Institute (NCI) | N/A |